Welcome to our dedicated page for Myriad Genetics news (Ticker: MYGN), a resource for investors and traders seeking the latest updates and insights on Myriad Genetics stock.
Myriad Genetics, Inc. (NASDAQ: MYGN) generates frequent news as a molecular diagnostic testing and precision medicine company. Its announcements often cover financial results, clinical research, product updates, and collaborations that shape how genetic and genomic testing is used in oncology, women’s health, and mental health care.
Investors and clinicians following MYGN news will see regular earnings releases and financial guidance updates, which the company also furnishes on Form 8-K. These updates describe trends in hereditary cancer testing, tumor profiling, prenatal screening, and pharmacogenomics, along with commentary on business performance and strategic priorities.
Scientific and medical conference activity is another major source of news. Myriad Genetics frequently reports new data on tests such as the MyRisk Hereditary Cancer Test, Precise MRD, FirstGene Multiple Prenatal Screen, Prequel Prenatal Screen, Foresight Carrier Screen, and the GeneSight Psychotropic test. Company communications highlight abstracts and posters at meetings like the San Antonio Breast Cancer Symposium and the National Society of Genetic Counselors Annual Conference.
News items also describe collaborations with partners including SOPHiA GENETICS, Clairity, and MagView, focused on areas such as liquid biopsy companion diagnostics and integrated breast cancer risk assessment platforms. Updates on leadership changes, credit facilities, and conference presentations at investor healthcare events are also part of the MYGN news flow.
This page provides a centralized view of these developments so readers can review Myriad Genetics’ latest financial disclosures, research milestones, product enhancements, and partnership announcements in one place.
Myriad Genetics (NASDAQ: MYGN) has launched a new patient home collection kit for its GeneSight® Psychotropic test, enabling DNA sample collection at home. This initiative responds to the rising mental health issues during the pandemic, as indicated by a Johns Hopkins survey showing a three-fold increase in psychological distress. The kit, ordered by healthcare providers, allows patients to collect their samples easily and submit them for analysis, with results available to clinicians in two days.
Myriad Genetics (NASDAQ: MYGN) announced the publication of a new study in Future Medicine validating the effectiveness of their myPath® Melanoma test. The study analyzed 181 skin lesions, revealing a 90.4% sensitivity and 95.5% specificity for indeterminate samples, with 43% representing malignant melanomas. These results affirm myPath Melanoma's capability to aid in accurate melanoma classification and underscore the importance of reliable diagnostic tools in early melanoma detection, impacting patient treatment outcomes.
Myriad Genetics (NASDAQ: MYGN) announced on June 15, 2020, that it has secured favorable coverage for its Prolaris® test from three new commercial health plans, including a major national provider. This expansion boosts access to prognostic testing for prostate cancer, now covering roughly 55 million lives. Nicole Lambert, president of Myriad International, noted that about 60% of men with prostate cancer can access the test, supporting better treatment decisions. The first policy took effect on June 8, 2020, while the second and third will become effective on June 15 and July 31, 2020, respectively.
Myriad Genetics (NASDAQ: MYGN) welcomes Palmetto GBA's final local coverage determination (LCD) for pharmacogenomic (PGx) testing, allowing broad coverage for psychiatric conditions. The LCD covers both single-gene and multi-gene tests but notes limited support for combinatorial tests. President Mark S. Verratti expresses optimism for the GeneSight Psychotropic test's coverage under this LCD. Clinical studies indicate improved outcomes for patients informed by GeneSight compared to standard treatment. This decision responds to increased mental health issues during the COVID-19 pandemic.
Myriad Genetics (NASDAQ: MYGN) announced a new study published in Psychiatry Research, showcasing the superiority of the GeneSight® Psychotropic test in predicting citalopram and escitalopram blood levels over single-gene tests. The study assessed 191 patients, demonstrating that GeneSight identifies more patients with significant gene-drug interactions, which might be missed by traditional methods.
Myriad Genetics (NASDAQ: MYGN) announced a prospective study showing that the EndoPredict test can predict responses to neoadjuvant therapy in ER+, HER2- early-stage breast cancer patients. Published in the European Journal of Cancer, the study involved 217 patients, demonstrating that 26.4% of those with high EndoPredict scores had a favorable tumor response to neoadjuvant chemotherapy, while all with low scores had poor responses. The test aims to aid personalized treatment decisions and enhance future clinical trial designs.
Myriad Genetics, Inc. (NASDAQ: MYGN) has elected Daniel K. Spiegelman to its Board of Directors, expanding the board to nine members. Spiegelman brings over 30 years of experience in biotechnology, having served as CFO at BioMarin Pharmaceuticals. He will also join the audit committee. The company also announced that John T. Henderson, M.D., a board member since 2004 and former chair, will retire at the Annual Meeting in December 2020. Myriad Genetics focuses on advancing molecular diagnostics and precision medicine, enhancing its product portfolio and revenue streams.
Myriad Genetics (NASDAQ: MYGN) announced FDA approval for its BRACAnalysis CDx test, a companion diagnostic for identifying men with metastatic castration-resistant prostate cancer (mCRPC) eligible for Lynparza (olaparib) treatment. This marks the seventh regulatory approval for the test, enhancing treatment options for patients with BRCA1/BRCA2 mutations. The PROfound trial demonstrated significant improvement in progression-free survival for patients treated with Lynparza compared to standard therapies. Myriad aims to improve patient outcomes through precision medicine.
Myriad Genetics (MYGN) announced FDA approval for its myChoice CDx test, a companion diagnostic for identifying advanced ovarian cancer patients with homologous recombination deficiency (HRD) who are eligible for first-line maintenance treatment with Lynparza (olaparib) and bevacizumab. The approval enhances precision medicine, potentially benefiting one in two women with HRD-positive ovarian cancer. Myriad's collaboration with AstraZeneca since 2007 continues to foster advancements in cancer diagnostics.